Benitec Biopharma Ltd ADR (BNTC) — Cash Flow-to-Debt Ratio
Benitec Biopharma Ltd ADR (BNTC) has a Cash Flow-to-Debt Ratio of -1.14x as of December 2025, meaning its operating cash flow of $-3.78 Million could theoretically repay -1% of its total liabilities ($3.32 Million) in one year. See BNTC financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Benitec Biopharma Ltd ADR Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Benitec Biopharma Ltd ADR across 13 annual periods. For the full cash flow conversion analysis, see Benitec Biopharma Ltd ADR cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Benitec Biopharma Ltd ADR (2013–2025)
Year-by-year debt coverage analysis for Benitec Biopharma Ltd ADR. Check Benitec Biopharma Ltd ADR cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -10.27x | $-23.59 Million | $2.30 Million | ▼ -162.6% |
| 2024 | -3.91x | $-19.40 Million | $4.96 Million | ▲ +7.5% |
| 2023 | -4.23x | $-18.01 Million | $4.26 Million | ▲ +17.8% |
| 2022 | -5.14x | $-15.90 Million | $3.09 Million | ▲ +45.1% |
| 2021 | -9.37x | $-12.83 Million | $1.37 Million | ▼ -87.3% |
| 2020 | -5.00x | $-7.54 Million | $1.51 Million | ▼ -375.5% |
| 2019 | 1.82x | $4.79 Million | $2.64 Million | ▲ +140.5% |
| 2018 | -4.49x | $-8.55 Million | $1.91 Million | ▲ +51.8% |
| 2017 | -9.32x | $-8.30 Million | $891.40K | ▲ +63.7% |
| 2016 | -25.70x | $-20.21 Million | $786.36K | ▼ -233.9% |
| 2015 | -7.70x | $-9.69 Million | $1.26 Million | ▼ -22.8% |
| 2014 | -6.27x | $-9.69 Million | $1.55 Million | ▲ +41.1% |
| 2013 | -10.64x | $-9.27 Million | $871.53K | — |